<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: O‚Å∂-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme </plain></SENT>
<SENT sid="1" pm="."><plain>MGMT promoter hypermethylation and epigenetic silencing often occur as early events in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, prognostic significance of MGMT alterations in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> remains uncertain </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Utilizing a database of 855 colon and <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancers</z:e> in two prospective cohort studies (the Nurses' Health Study and the Health Professionals Follow-up Study), we detected MGMT promoter hypermethylation in 325 tumors (38%) by MethyLight and loss of MGMT expression in 37% (247/672) of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> by immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>We assessed the CpG island methylator phenotype (CIMP) using eight methylation markers [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1], and LINE-1 (L1) hypomethylation, TP53 (p53), and microsatellite instability (MSI) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: MGMT hypermethylation was not associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific mortality in univariate or multivariate Cox regression analysis [adjusted hazard ratio (HR) = 1.03; 95% confidence interval (CI), 0.79-1.36] that adjusted for clinical and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> features, including CIMP, MSI, and BRAF mutation </plain></SENT>
<SENT sid="6" pm="."><plain>Similarly, MGMT loss was not associated with patient survival </plain></SENT>
<SENT sid="7" pm="."><plain>MGMT loss was associated with G&gt;A mutations in KRAS (p = 0.019) and PIK3CA (p = 0.0031) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Despite a well-established role of MGMT aberrations in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, neither MGMT promoter methylation nor MGMT loss serves as a prognostic biomarker in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>